New One Minute Rapid-Acting Insulin: Lyumjev

Diabetesincontrol.com

Klicken Sie hier, um Diabetesincontrol.com zu abonnieren

Kategorien: Gesundheit | Wohlfahrt Gesundheit Bildung Alter: 14 - 18 Jahr 19 - 30 Jahr 31 - 64 Jahre

Laden...

4 jahre vor

Html
Text

Plus: cinnamon for prediabetes; Synjardy tentative approval; meds & COVID-19; low-carb effect

July 25, 2020 : Issue #1052

TOP STORIES - Diabetes News & Research

New One Minute Rapid-Acting Insulin: Lyumjev
Glucose-Lowering Medications and COVID-19 Outcomes in Patients with Diabetes
The Low-Carbohydrate Effect

Letter from the Editor
Regardless of which side of the political coin you are on, we seem to see that as time goes by and new data comes in, there is a definite benefit to masks for the prevention of the spread of COVID-19. First there was a small benefit; then they proved it blocked the spread from the wearer; and now the data shows that the wearer is also protected.
This kind of correlates with the data on low carb diets and glucose control. In the 70’s the ADA was totally against low carb; finally in the late 90’s they begrudgingly said it might work; and it wasn’t more than 10 years ago that they finally agreed that low carb programs work.
We at Diabetes In Control have always taught low carb to our patients, and now our Intern Bernice Ford, from FAMU College of Pharmacy, has put together a great article on how a low carb program can actually reverse type 2 diabetes.
*****************************
We can make a difference!
*****************************
Dave Joffe
Editor-in-chief

Newsflash: FDA Gives Tentative Approval for Synjardy

The FDA has given a tentative nod to Alembic for its generic Synjardy (empagliflozin and metformin hydrochloride tablets) in dosage strengths of 5 mg/500 mg, 5 mg/1000 mg, 12.5 mg/500 mg, and 12.5 mg/1000 mg. Alembic currently is in litigation with Boehringer Ingelheim,and the launch of the product will depend on litigation outcome.

Did You Know? There’s a Possible Safe Treatment to Prevent Prediabetes from Becoming Diabetes:

New research from a double-blind, placebo-controlled trial suggests supplemental cinnamon could improve fasting plasma glucose and glucose tolerance among patients with prediabetes. Results of the 12-week study, which was conducted by an international team of investigators, indicate cinnamon could be a durable, cost-effective approach to reducing progression from prediabetes to type 2 diabetes.
The trial randomized 51 adults with prediabetes to receive 500 mg of cinnamon or placebo 3 times per day for 12 weeks. Upon analysis, investigators found changes in fasting plasma glucose levels were not different between the 2 groups at 6 weeks. Conversely, 12-week assessments indicated fasting glucose rose after 12 weeks with placebo, yielding a mean between-group difference of 5 mg/dL (114±8 vs. 108±11; P <.01). Results also indicated cinnamon was associated with a significant reduction in the area under the curve of plasma glucose during the OGTT from baseline to 12 weeks (21,389±3858 vs. 19946 ± 4070 mg/dL/120 min; P <.05). In comparison, no change was observed among patients in the placebo group. Additionally, cinnamon was associated with a significant decrease in plasma glucose at the 2-hour time point of the OGTT from baseline to 12 weeks (-20±27 mg/dL; P <.01). Investigators also pointed out no adverse events were observed in either study group during the 12-week study period. From the results of the study, it was concluded that cinnamon may improve blood sugar control in people with prediabetes and may slow the progression to type 2 diabetes.
This study, "Influence of cinnamon on glycemic control in subjects with prediabetes: a randomized controlled trial," was published July 20, 2020, Journal of The Endocrine Society

Diabetes in Control gratefully acknowledges the assistance of the following pharmacy doctoral candidates in the preparation of this week’s newsletters:

Brianna Belton, PharmD. Candidate, Florida Agricultural & Mechanical University, College of Pharmacy and Pharmaceutical Sciences

Bernice Ford, 2021 PharmD Candidate, Florida Agricultural & Mechanical University, College of Pharmacy and Pharmaceutical Sciences

Zahra Hashemy, PharmD. Candidate, USF Taneja College of Pharmacy

Maya Palmer, PharmD. Candidate, Florida A&M University College of Pharmacy

Melinda Rodriguez, PharmD Candidate 2021, Lake Erie College of Osteopathic Medicine – L|E|C|O|M School of Pharmacy

Olivia Shenouda. PharmD. Candidate, Florida A&M University, School of Pharmacy

About LaterPay: You will notice that some of our articles are now marked with a small credit card icon. This means you will be asked to pay a small fee to access the full article text (the cost is $0.39 per article, and you will be charged only after you have reached $5.00 in article views). The costs of producing a newsletter like Diabetes in Control have been increasing, which is why we are asking our readers to help support our ability to continue to bring you quality information about diabetes through charging a minimal price to read certain articles. Thank you for helping to support Diabetes in Control.

Your Friends in Diabetes Care
Steve and Dave
Diabetes In Control
810 Bear Tavern Road Suite 102
Ewing, NJ, 08628
USA
www.diabetesincontrol.com

©2020 HIPER, LLC. All rights reserved.
This email was sent by eHealthcare Solutions on behalf of: Diabetes In Control
810 Bear Tavern Rd, Suite 102
Ewing, NJ, 08628, United States
DiabetesInControl.com | Contact Us
Subscription Center | Update Profile
Unsubscribe

Teilen auf

Laden...

Weitere Newsletter von Diabetesincontrol.com

Laden...

Andere Kategorien anzeigen

Gesundheit | Wohlfahrt Gesundheit Bildung

New One Minute Rapid-Acting Insulin: Lyumjev

July 25, 2020 : Issue #1052

TOP STORIES - Diabetes News & Research

Newsflash: FDA Gives Tentative Approval for Synjardy

TOP STORIES - Diabetes News and Research

Did You Know? There’s a Possible Safe Treatment to Prevent Prediabetes from Becoming Diabetes:

Diabetes in Control gratefully acknowledges the assistance of the following pharmacy doctoral candidates in the preparation of this week’s newsletters:

Teilen auf

Weitere Newsletter von Diabetesincontrol.com

Verwandte Newsletter

Andere Kategorien anzeigen